# Apexian Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/apexian-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Indianapolis, US
- Website: www.apexianpharma.com
- Total disclosed funding: $2.5M
- Latest round: Series A (Nov 29, 2017)
- Investors on record: 4

## About

Apexian Pharmaceuticals, Inc. is a biotechnology firm focused on developing innovative therapeutic solutions for cancer and inflammation-related diseases through its lead drug candidate, APX3330.Founded in 2007 and headquartered in Indianapolis, Indiana, Apexian Pharmaceuticals, Inc. specializes in drug development targeting the APE1/Ref-1 redox protein. The firm has undergone strategic pivots to enhance its clinical focus and is led by CEO David Broecker. The company has been involved in eight financing deals, with the most recent deal occurring on July 11, 2018, where it raised USD 2.8 mn in venture financing.Apexian Pharmaceuticals' core product, APX3330, is a novel drug candidate targeting the APE1/Ref-1 redox protein, linked to various cancers and inflammatory conditions. It has shown substantial anti-cancer and anti-inflammatory effects in pre-clinical studies, with a current clinical development program including a Phase 2 trial for treating diabetic retinopathy. The company primarily serves patients with advanced cancers and inflammation-related diseases in North America.The exact revenue details for Apexian Pharmaceuticals are not specified. The company's business model is centered on clinical trials and partnerships with healthcare providers, involving B2B transactions with hospitals and medical research institutions for the development and distribution of APX3330. Their revenue structure may include collaborations with clinical organizations to facilitate patient enrollment and potential licensing agreements with pharmaceutical companies in the oncology and inflammatory disease markets.Apexian Pharmaceuticals plans to utilize the USD 2.8 mn raised in July 2018 to further develop APX3330 and expand its clinical trials. The company aims to initiate trials for new products targeting additional indications while exploring opportunities to enter broader international markets beyond North America. This expansion strategy is anticipated to be implemented in the next few years, aligning with their commitment to address unmet medical needs in oncology and inflammatory diseases.

## Funding rounds

- Series A, Nov 29, 2017 — Elevate Ventures
- Seed, Jul 24, 2013, $2.5M — BioCrossroads
- Seed, Nov 17, 2010 — Pearl Street Venture Funds, Innovate Indiana Fund

## Investors

- Pearl Street Venture Funds (https://capitalatlas.ai/funds/pearl-street-venture-funds) — Seed
- Innovate Indiana Fund — Seed
- BioCrossroads (https://capitalatlas.ai/funds/biocrossroads) — Seed
- Elevate Ventures (https://capitalatlas.ai/funds/elevate-ventures) — Series A